NEW YORK (GenomeWeb News) – Molecular Detection today said that it has raised $3.3 million through a Series C financing, which it will use to support the launch of its rapid, molecular Staphylococcus aureus test.

In addition to the financing, Molecular Detection said that it has named Todd Wallach to serve as CEO of the firm. Wallach previously was CFO of Aton Pharma and was a VP of finance at Acquity Pharmaceuticals, before that firm was acquired by Opko Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.